Key messages Stephen S Lim, et al. Lancet 2007; 370: 2054-62.

Slides:

Advertisements

Similar presentations

WHO CVD Atlas WHO Stroke Atlas The Burden of CVD in Asia: Stroke Deaths by Country,

Advertisements

Absolute cardiovascular disease risk Assessment and Early Intervention Dr Michael Tam Lecturer in Primary Care

Stroke Issues & prevention. Agenda  Impact of Stroke –Definitions –Epidemiology –Risk factors  Management of Stroke –Acute management –Primary & Secondary.

E NHANCING C OMPREHENSIVE HIV C ARE : Addressing Cardiovascular Disease (CVD) and other Noncommunicable Diseases (NCDs) Kwasi Torpey MD PhD MPH FGCP Deputy.

Stroke - the size of the problem. What is a stroke? What is a transient ischaemic attack? What is the size of the problem?

Non-communicable diseases David Redfern

HYPERLIPIDAEMIA. 4S 4444 patients –Hx angina or MI –Cholesterol Simvastatin 20mg (10-40) vs. placebo FU 5 years  total cholesterol 25%;  LDL.

Health system expenditure on disease and injury in Australia: Presentation to OECD Meeting of Health Accounts Experts / Sept 2005 Mr John Goss Principal.

The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial ALLHAT study overview Double-blind, randomized trial to determine whether.

Frank B. Hu et al N Engl J Med 2004; 351: Body-Mass Index and Relative Risk of Death from All Causes during 24 Years of Follow-up.

Measurement Measuring disease and death frequency FETP India.

Measuring disease and death frequency

Kotseva K, et al. Eur J Cardiovasc Prev Rehabil 2009 Mar 12 [Epub]

By Judith Graham heart-attacks/ The Deadly Threat of Silent Heart Attacks.

10 Points to Remember on the Assessment of Cardiovascular RiskAssessment of Cardiovascular Risk Summary Prepared by Melvyn Rubenfire, MD.

Sources of Limited Access to Treatment High Cost of Treatment Lack of Pilot Projects Lack of Evidence Lack of Policy Lack of Demand.

The Rising Prevalence of NCDs: Implications for Health Financing and Policy Charles Holmes, MD, MPH Office of the U.S. Global AIDS Coordinator Department.

Aim To determine the effects of a Coversyl- based blood pressure lowering regimen on the risk of recurrent stroke among patients with a history of stroke.

To assess the prognostic value of variability in home-measured blood pressure (BP) and heart rate (HR) in a general population. Objective: Methods: BP.

Antithrombotic Trialists’ (ATT) Collaboration. Lancet 2009;373:

How can you estimate simply the cardiovascular risk of your patients?

Lancet 373: , 2009 Baseline Characteristics of Participants and Study Design of Clinical Trials to Compare Intensive glucose- lowering versus.

National and subnational mortality effects of major metabolic risk factors and smoking in Iran: a comparative risk assessment Scientific Webinars Farzadfar.

Innovations in Management of Cardiovascular Disease for Global Health

Slide 1 Downloaded from Population Impact of Losartan Use on Stroke in the European Union (EU)

Background There are 12 different types of medications to lower blood sugar levels in patients with type 2 diabetes. It is widely agreed upon that metformin.

7 April 2013 WORLD HEALTH DAY. World Health Day 2 On 7 April 1948, the World Health Organization (WHO) was created. Since then, WHO named April 7 as World.

Age-standardized mortality from ischaemic heart disease in European regions (men; age group years; year 2000) J Muller-Nordhorn, et al. Eur Heart.

Dr. Rohit A, Dr Balu P S Public Health Specialist [ NCD] India

Slide Source: Lipids Online Slide Library Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) Design Sever PS et al. J Hypertens 2001;19:1139–1147.

Distribution of metabolic syndrome (MS) components by age and gender Zhao D, et al. Am J Cardiol 2007;100:835– 839.

Ridker PM, et al. Lancet 2009;373: Baseline clinical characteristics of the study population in the placebo and rosuvastatin groups according.

 Ischaemic heart disease reduces blood supply to the heart muscles and is one of the major cardiovascular diseases.

2007 Hypertension as a Public Health Risk January, 2007.

Meeting the Challenge of Non-Communicable Diseases Lecture 14.

The Burden of Chronic Diseases in the Developing World Stephen J. Spann, M.D., M.B.A. Professor and Chairman Department of Family and Community Medicine.

Lessons from Uganda: Chronic Disease and Palliative Care in a Resource Limited Setting Kuang-Ning Huang, MD UVM Family Medicine Residency PGY3.

Over Time Additional Risk Factors Can Progress: Effect of Cholesterol and BP on CHD Risk in MRFIT Trial

Microvascular disease and risk of cardiovascular events among individuals with type 2 diabetes: a population-level cohort study Dr Jack R W Brownrigg,

Context and Objectives

Projected global distribution of total deaths (58 million) by major cause, 2005 Kathleen Strong et al, Lancet 2005; 366: 1578–82.

Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies The Emerging.

Copyright © 2007 American Medical Association. All rights reserved.

Comparison of baseline characteristics in participants who subsequently had an incident cardiovascular event or new-onset diabetes in the Prospective.

An assessment of community health workers' ability to screen for cardiovascular disease risk with a simple, non-invasive risk assessment instrument in.

Risk factor thresholds: their existence under scrutiny

Cardiovascular risk factors: are they useful screening tests?

Association of low eosinophil and lymphocyte counts with different initial presentations of cardiovascular disease over the first 6 months ‘Low eosinophils’

Teaching Tool: Blood Pressure Classification

Cardiovascular disease, chronic kidney disease, and diabetes mortality burden of cardiometabolic risk factors from 1980 to 2010: a comparative risk assessment

Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies The Emerging.

Insights from the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT)

VALUE Trial design: Hypertensive patients at high cardiovascular risk were randomized to valsartan (n = 7,649) vs. amlodipine (n = 7,596). Results (p =

Relative risk of major events with atenolol vs placebo

Key messages Dele O Abegunde, et al. Lancet 2007; 370:

An assessment of community health workers' ability to screen for cardiovascular disease risk with a simple, non-invasive risk assessment instrument in.

Key messages Perviz Asaria, et al. Lancet 2007; 370:

Relative risks of clinical events for primary and secondary prevention with selected drugs Thomas A Gaziano, et al. Lancet 2006; 368:

Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies The Emerging.

Baseline Characteristics of the Subjects*

Kotseva K, et al. Lancet 2009;373:929-40

The proportion of patients confronted with a cardiovascular risk factor (CVRF) they were previously unaware of, referring to the instrument based tests.

An ACCORD BP sub-analysis HR: 1.06; 95%CI: ; P=0.61

EMPA-REG OUTCOME: Cumulative incidence of the primary outcome

Connie W. Tsao et al. JCHF 2016;4:

An ACCORD BP sub-analysis HR: 1.06; 95%CI: ; P=0.61

ROC curves for cardiovascular events, all-cause mortality, and disease progression. ROC curves for cardiovascular events, all-cause mortality, and disease.

Hazard ratios, with 95% confidence intervals as floating absolute risks, as estimate of association between category of updated mean haemoglobin A1c concentration.

HR for mortality in ischemic heart disease.

Adjusted HRs for death from any cause and death from specific causes among patients with type 1 diabetes. Adjusted HRs for death from any cause and death.

Presentation transcript:

Key messages Stephen S Lim, et al. Lancet 2007; 370:

Countries that account for 80% of global chronic disease deaths in low-income and middle-income countries Stephen S Lim, et al. Lancet 2007; 370:

Main model parameters Stephen S Lim, et al. Lancet 2007; 370:

Example of an absolute risk chart using age, sex, smoking status, systolic blood pressure, and body-mass index *Numbers are 10-year risk of fatal ischaemic heart disease or cardiovascular events in Mexico Stephen S Lim, et al. Lancet 2007; 370:

Patterns of scale-up of a multidrug regimen for patients at high risk of cardiovascular disease by Commission on Macroeconomics in Health (CMH) category, expressed as a proportion of those accessing health services Stephen S Lim, et al. Lancet 2007; 370:

Effects of diff erent individual drugs, measured as relative risk, on fatal and non-fatal ischaemic heart disease and cerebrovascular disease Stephen S Lim, et al. Lancet 2007; 370:

Patient cost parameters Stephen S Lim, et al. Lancet 2007; 370:

Cumulative thousands of deaths averted with a multidrug regimen for the prevention of cardiovascular disease by sex, Stephen S Lim, et al. Lancet 2007; 370:

Person-years of treatment and number of deaths averted by age and sex, Stephen S Lim, et al. Lancet 2007; 370:

Cumulative financial cost of scaling up a multidrug regimen for the prevention of cardiovascular disease, Stephen S Lim, et al. Lancet 2007; 370:

Average yearly cost (US$ per head) of scaling up a multidrug regimen for the prevention of cardiovascular disease by country, Stephen S Lim, et al. Lancet 2007; 370:

Average yearly cost (proportion of current health expenditure) of scaling up a multidrug regimen for the prevention of cardiovascular disease by country, Stephen S Lim, et al. Lancet 2007; 370: